UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 165

Sortiert nach

Mechanisms regulating resistance to inhibitors of topoisomerase II

Frontiers in pharmacology, 2013-01, Vol.4, p.89

2013

Volltextzugriff (PDF)

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer

British journal of cancer, 2018-10, Vol.119 (9), p.1060-1066

2018

Volltextzugriff (PDF)

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance

Proceedings of the National Academy of Sciences - PNAS, 2011-11, Vol.108 (46), p.18708-18713

2011

Volltextzugriff (PDF)

RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers

Cancers, 2020-03, Vol.12 (3), p.620

2020

Volltextzugriff (PDF)

Clear Cell Tubulopapillary Renal Cell Carcinoma: A Study of 36 Distinctive Low-grade Epithelial Tumors of the Kidney

The American journal of surgical pathology, 2010-11, Vol.34 (11), p.1608-1621

2010

Volltextzugriff (PDF)

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy

Gynecologic oncology, 2018-04, Vol.149 (1), p.155-162

2018

Volltextzugriff (PDF)

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint

Nucleic acids research, 2017-06, Vol.45 (10), p.5995

2017

Volltextzugriff (PDF)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma

The Journal of pathology, 2019-07, Vol.248 (3), p.352-362

2019

Volltextzugriff (PDF)

Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high‐grade serous ovarian cancer

International journal of cancer, 2016-02, Vol.138 (3), p.679-688

2016

Volltextzugriff (PDF)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer

Neoplasia (New York, N.Y.), 2018-03, Vol.20 (3), p.280-288

2018

Volltextzugriff (PDF)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer

Frontiers in oncology, 2020-08, Vol.10, p.1354-1354

2020

Volltextzugriff (PDF)

Small Molecules That Reactivate p53 in Renal Cell Carcinoma Reveal a NF-κB-Dependent Mechanism of p53 Suppression in Tumors

Proceedings of the National Academy of Sciences - PNAS, 2005-11, Vol.102 (48), p.17448-17453

2005

Volltextzugriff (PDF)

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia

Scientific reports, 2020-03, Vol.10 (1), p.5486, Article 5486

2020

Volltextzugriff (PDF)

Dexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines

Leukemia & lymphoma, 2021-01, Vol.62 (2), p.473-477

2021

Volltextzugriff (PDF)

Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer

Gynecologic oncology, 2016-06, Vol.141 (3), p.608-615

2016

Volltextzugriff (PDF)

Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs

Urologic oncology, 2014, Vol.32 (1), p.1-4

2014

Volltextzugriff (PDF)

Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1

Gynecologic oncology reports, 2018-02, Vol.23 (C), p.41-44

2018

Volltextzugriff (PDF)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer1

Neoplasia (New York, N.Y.), 2018-03, Vol.20 (3), p.280-288

2018

Volltextzugriff (PDF)

Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials

Genome medicine, 2011-12, Vol.3 (12), p.79-79

2011

Volltextzugriff (PDF)

Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors

Current oncology reports, 2010-03, Vol.12 (2), p.102-108

2010

Volltextzugriff (PDF)

Inhibition of Proteasome Activity by Bortezomib in Renal Cancer Cells Is p53 Dependent and VHL Independent

Anticancer research, 2009-08, Vol.29 (8), p.2961-2969

2009

Volltextzugriff (PDF)

Role of the 18:1 lysophosphatidic acid-ovarian cancer immunoreactive antigen domain containing 1 (OCIAD1)-integrin axis in generating late-stage ovarian cancer

Molecular cancer therapeutics, 2010-06, Vol.9 (6), p.1709-1718

2010

Volltextzugriff (PDF)

Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion

Gynecologic oncology, 2008-05, Vol.109 (2), p.226-233

2008

Volltextzugriff (PDF)

Immunotherapy clinical trials suggest predictive immune-related biomarkers are tissue specific

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14206-e14206

2019

Volltextzugriff (PDF)

1 – 25 von 165

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(154)

Publikationsform

Sprache

Englisch
(164)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Life Sciences & Biomedicine
(80)
Humans
(66)
Oncology
(51)
Biological And Medical Sciences
(45)
Medical Sciences
(43)
Female
(34)
Pharmacology. Drug Treatments
(32)
Animals
(29)
Antineoplastic Agents
(26)
Middle Aged
(25)
Aged
(23)
Mice
(22)
Male
(21)
Adult
(20)
Tumors
(19)
Drug Resistance
(17)
Pharmacology & Pharmacy
(16)
Dna Topoisomerases, Type Ii - Metabolism
(15)
General Aspects
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mechanisms regulating resistance to inhibitors of topoisomerase II

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance

RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers

Clear Cell Tubulopapillary Renal Cell Carcinoma: A Study of 36 Distinctive Low-grade Epithelial Tumors of the Kidney

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma

Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high‐grade serous ovarian cancer

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium

Small Molecules That Reactivate p53 in Renal Cell Carcinoma Reveal a NF-κB-Dependent Mechanism of p53 Suppression in Tumors

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia

Dexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines

Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer

Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs

Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer1

Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials

Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors

Inhibition of Proteasome Activity by Bortezomib in Renal Cancer Cells Is p53 Dependent and VHL Independent

Role of the 18:1 lysophosphatidic acid-ovarian cancer immunoreactive antigen domain containing 1 (OCIAD1)-integrin axis in generating late-stage ovarian cancer

Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion

Immunotherapy clinical trials suggest predictive immune-related biomarkers are tissue specific

Suchergebnisse filtern